Related Experiment Videos

Cystinuria in children

European Urology
|January 1, 1981
PubMed

Insights

Alpha-mercaptopropionylglycine (MPG) effectively treats cystinuria in children, but high doses may cause nephrotic syndrome. Urine alkalinization and dilution are crucial for managing this condition.

Area of Science:

  • Pediatric Nephrology
  • Urology

Background:

  • Cystinuria is a genetic disorder characterized by the formation of renal calculi (kidney stones).
  • Management of cystinuria in children requires effective therapeutic strategies to prevent stone recurrence and complications.

Purpose of the Study:

  • To evaluate the efficacy and safety of alpha-mercaptopropionylglycine (MPG) in pediatric patients with cystinuria and renal calculi.
  • To identify factors contributing to treatment failure and recurrence in a pediatric cohort.

Main Methods:

  • Retrospective analysis of 7 pediatric patients diagnosed with cystinuria and renal calculi.
  • Assessment of treatment outcomes including surgical intervention and alpha-mercaptopropionylglycine (MPG) therapy.
  • Monitoring of urinary cystine levels and adverse events.

Main Results:

  • Satisfactory results were achieved in 5 out of 7 children treated with a combination of surgical intervention and MPG.
  • Recurrences were observed in 2 children, with underlying causes discussed.
  • MPG therapy demonstrated efficacy but was associated with nephrotic syndrome at doses exceeding 50 mg/kg/day.
  • Urinary cystine levels below 200 mg/day were not always indicative of safety in children.

Conclusions:

  • Alpha-mercaptopropionylglycine (MPG) is an effective treatment for pediatric cystinuria, but careful dose monitoring is essential to avoid adverse effects like nephrotic syndrome.
  • Urine alkalinization and dilution remain fundamental components of cystinuria management in children.
  • Further investigation into the causes of recurrence is warranted to optimize long-term treatment strategies.

Related Concept Videos